Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure patients may soon get meds through a patch instead of an IV

NCT ID NCT04846816

Symptom relief Sponsor: SQ Innovation, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a new patch-like device that delivers the heart failure drug furosemide under the skin. Twenty hospitalized heart failure patients received a single dose to see if it is safe and works well. The goal is to find a simpler way to give this medication without needles or IVs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
furosemide delivered via a patch infusor device
What this could lead to
If successful, this could offer a more convenient way to deliver furosemide for heart failure, potentially reducing hospital stays.
What could go wrong
This is a very early phase 1 trial with only 20 participants, so results may not apply to all patients. The device could fail or cause skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

20 people

The number who actually took part.

Started

May 2021

Finished

Aug 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Written informed consent * Male or female ≥18 years of age * Meet ESC criteria for diagnosis of HF(4) * Inpatient with a primary diagnosis of HF requiring treatment with intravenous furosemide at dose Exclusion Criteria: * • Unable to consent to inclusion in study due to lack of capacity * Requiring treatment with intravenous furosemide at dose \>200 mg per day as determined by the usual care team * Current inotropes, vasopressors or intra-aortic balloon pump therapy * Concomitant use of diuretics in 12 hours preceding administration of study drug with SQIN-Infusor * Systolic blood pressure (SBP) \<90 mmHg * Pregnancy or breastfeeding * Left sided valve disease with planned surgery or percutaneous intervention * Type 1 myocardial infarction during index hospitalisation (type 2 myocardial infarctions are allowed)(5) * Any surgical or medical condition which prevents patient from ambulation during the infusion * Renal impairment, defined as eGFR \< 30 mL/min/1.73 m2 at screening. * Patient on active cardiac transplant waiting list * Potassium \<3.0 mmol/L * Potassium \>6.0 mmol/L * Sodium \<125 mmol/L * Any contraindications for furosemide administration as per furosemide SmPC * Any surgical or medical conditions, which in the opinion of the investigator may pose an undue risk to the subject, interfere with participation in the study or which may affect the integrity of the data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde

    Glasgow, Glasgow, G51 4TF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.